Health Systems Prepare for CAR T-Cell Therapy

The global rollout of CAR T-cell therapy has revealed significant gaps in healthcare system readiness across several regions. The independent report by the IQVIA Institute for Human Data Sciences highlights these discrepancies, noting that the transformative treatment for blood cancer is often hindered by logistical and structural barriers rather than a lack of clinical efficacy.

The study examines seven countries—France, Germany, Spain, Italy, the United Kingdom, Canada, and Australia. It finds that while the technology exists, the infrastructure to support it varies wildly. The report notes that some countries are only treating a small fraction of eligible patients, with utilisation rates dropping as low as 11% in certain cases.

This gap between the promise of innovation and the reality on the ground is a persistent issue in the global haemato-oncology community. The success of CAR T-cell therapy, which harnesses the body’s immune system to target cancer, hinges not just on the drug itself but on a complex network of referral pathways, infrastructure, and reimbursement policies.

It is difficult to overstate the stakes involved. Unless action is taken to address these access challenges, the report warns that lives lost to cancer in Europe are projected to increase by more than 24% by 2035.

Why the system struggles to keep up

Healthcare providers identify three primary obstacles preventing patients from receiving this potentially life-saving treatment. The first is the clarity of referral pathways, which are often unclear or underutilised. In Spain, 61% of physicians cite delays between referral and treatment as a major hurdle, a challenge mirrored in Italy and Germany where the lack of standardised pathways can delay care.

Second, treatment centre capacity is limited in most jurisdictions. Six out of the seven countries studied indicated that their facilities face constraints that make it difficult to meet the rising demand for the therapy. Many centres simply lack the resources or physical infrastructure to handle all eligible patients. Finally, the absence of full national strategies acts as a significant impediment; five of the nations investigated do not currently have a coordinated plan to implement CAR T-cell therapy access.

The implications of these structural issues are serious. Delays in treatment can lead to disease progression, which reduces the likelihood of a successful outcome. More than 50% of patients in some countries face waits of approximately two months for care. In Italy, while 80% of diffuse large B-cell lymphoma (DLBCL) patients receive treatment after referral, only 38% do so within a month of being referred. These waiting periods can render patients ineligible for therapy entirely, creating a disparity based on geography or resource availability rather than clinical need.

While the report recommends streamlining referral processes and developing national strategies with clear timelines and performance metrics, the path forward remains complex. The financial and operational demands of scaling these therapies suggest that current systems may struggle to adapt quickly enough without substantial policy intervention. Policymakers face the difficult task of balancing the high cost of personalized medicine with the need for equitable distribution across diverse healthcare settings.

Policy and standardisation as a solution

Healthcare authorities and policymakers have a critical role to play in closing these access gaps. By setting regulations that promote access and allocating resources to support treatment centres, governments can begin to dismantle the barriers identified in the research. European policymakers are particularly positioned to lead this effort, given the diversity of healthcare systems across the region.

Collaboration among nations can help standardize data collection and reporting systems for CAR T-cell therapy outcomes. This would allow for better monitoring of treatment effectiveness and the identification of disparities, enabling evidence-based policy making. The European Commission’s Beating Cancer Plan outlines a new approach to prevention and care, but specific implementation strategies for complex cell therapies remain a necessary focus for local authorities.